23andMe Investor Presentation Deck

Strategic Collaboration With gsk $300M equity investment 50/50 shared costs and profits Access to GSK technology and platforms "Our work with 23andMe is exceeding expectations and helping us advance a new way of thinking about drug discovery, one driven by genetics and the DNA we inherit. The insights of why some people are protected from or are at greater risk for certain diseases can lead to genetically validated targets that are at least twice as successful in clinical trials." Dr. Hal Barron, Chief Scientific Officer & President R&D, GSK (2021)

View entire presentation